Molecular Design of Anticancer Drug Leads Based on Three-Dimensional Quantitative Structure–Activity Relationship
Authors:
- 26 July 2011
- journal article
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 51 (8) , 1999-2006
Abstract
Heat shock protein 90 (Hsp90) takes part in the developments of several cancers. Novobiocin, a typically C-terminal inhibitor for Hsp90, will probably used as an important anticancer drug in the future. In this work, we explored the valuable information and designed new novobiocin derivatives based on a three-dimensional quantitative structure-activity relationship (3D QSAR). The comparative molecular field analysis and comparative molecular similarity indices analysis models with high predictive capability were established, and their reliabilities are supported by the statistical parameters. Based on the several important influence factors obtained from these models, six new novobiocin derivatives with higher inhibitory activities were designed and confirmed by the molecular simulation with our models, which provide the potential anticancer drug leads for further research.Keywords
This publication has 30 references indexed in Scilit:
- Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell LinesThe Journal of Organic Chemistry, 2008
- High-throughput screening for Hsp90 ATPase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- HSP90 and the chaperoning of cancerNature Reviews Cancer, 2005
- The Stress Response: Implications for the Clinical Development of Hsp90 InhibitorsCurrent Cancer Drug Targets, 2003
- Heat shock protein 90 as a molecular target for cancer therapeuticsCancer Cell, 2003
- Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperoneCancer Detection Prevention, 2002
- HSP90 as a new therapeutic target for cancer therapy: the story unfoldsExpert Opinion on Biological Therapy, 2002
- Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical ActivityInvestigational New Drugs, 1999
- Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and GeldanamycinJournal of Medicinal Chemistry, 1999
- The Hsp90 complex—a super-chaperone machine as a novel drug targetBiochemical Pharmacology, 1998